Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Protein polybromo-1 (PBRM1) is a subunit of the SWI/SNF (specifically PBAF) chromatin-remodeling complex, encoded by the PBRM1 gene in humans[1][4]. It contains bromodomains and BAH domains, enabling recognition of acetylated lysine residues—such as those on the tumor suppressor protein p53 and on histones—thereby regulating gene expression, chromatin structure, and genomic stability[3][6]. PBRM1 functions as a tumor suppressor, particularly in clear cell renal cell carcinoma (ccRCC)[1][2][5]. Mutations or deletions of PBRM1 are frequent in ccRCC and are associated with altered chromatin structure, deregulated gene expression, and distinct clinical outcomes compared to other tumor suppressor pathways[2]. PBRM1 contributes to the regulation of cell proliferation, cell cycle progression, and DNA damage response. Although not yet a direct pharmacological target, PBRM1 is an important biomarker, and its status can influence therapeutic response to immune checkpoint inhibitors and other cancer treatments[5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Protein polybromo-1 (PBRM1).